Entrectinib expands the range of treatment options for advanced NTRK+ solid tumours and ROS1+ NSCLC, and may be of particular value in patients with existing CNS metastases and those who are at risk of developing CNS metastases. READ ARTICLE
Drugs DOI:10.6084/m9.figshare.14150207
Authors: James E Frampton